Article info

Download PDFPDF

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Authors

  1. a +82-2-2228-8132 unchung8{at}yuhs.ac
  2. b Tobias.Arkenau{at}HCAHealthcare.co.uk
  3. c jyunlee{at}skku.edu
  4. d RHA7655{at}yuhs.ac
  5. e ohdoyoun{at}snu.ac.kr
  6. f lucjanwyrwicz{at}gmail.com
  7. g ykkang{at}amc.seoul.kr
  8. h hmodoctor{at}snubh.org
  9. i jri123c{at}gmail.com
  10. j h00285{at}paik.ac.kr
  11. k kemenym{at}nychhc.org
  12. l ulrich.keilholz{at}charite.de
  13. m bohuslav.melichar{at}fnol.cz
  14. n alain.mita{at}cshs.org
  15. o ruth.plummer{at}newcastle.ac.uk
  16. p denis.smith{at}chu-bordeaux.fr
  17. q arnoldgelb{at}gmail.com
  18. r huiling.xiong{at}emdserono.com
  19. s janet.hong{at}emdserono.com
  20. t vikramkchand{at}gmail.com
  21. u hsafran{at}lifespan.org
View Full Text

Citation

Chung HC, Arkenau H, Lee J, et al
Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Publication history

  • Received October 24, 2018
  • Accepted January 13, 2019
  • First published February 4, 2019.
Online issue publication 
February 04, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.